X4 Pharmaceuticals, Inc. (XFOR)
After hours:
| Previous close | 1.1200 |
| Open | 1.1300 |
| Bid | 1.0600 x 300 |
| Ask | 1.1200 x 2200 |
| Day's range | 1.0700 - 1.1400 |
| 52-week range | 0.5720 - 2.5750 |
| Volume | |
| Avg. volume | 3,072,686 |
| Market cap | 185.571M |
| Beta (5Y monthly) | 0.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5700 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.12 |
GlobeNewswireX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee
- GlobeNewswire
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024. The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United Stat
- Reuters
UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older, sending its shares up 16% before the bell. X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome. The decision is based on a late-stage study where the therapy showed 60% reduction in infection rate compared to placebo when tested in patients with WHIM syndrome.
